Trial Profile
A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Jun 2013
Price :
$35
*
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 01 Jun 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 01 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Feb 2010 Planned end date changed from 1 Jun 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.